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The precise cause of Dupuytren disease remains incompletely understood. Genetic factors are clearly involved in the pathogenesis of Dupuytren disease, as illustrated by family studies and by a genomewide association study.1–3 In addi-tion, environmental factors are believed to play a 
role in the development of the condition. Dupuy-
tren disease has been observed in association with 
hand trauma, manual work, smoking, and exces-
sive alcohol consumption.4–7 Moreover, Dupuytren 
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Background: The role of diabetes mellitus, liver disease, and epilepsy as risk fac-
tors for Dupuytren disease remains unclear. In this systematic review and meta-
analysis, the strength and consistency of these associations were examined.
Methods: The MEDLINE, EMBASE, and Web of Science databases were searched 
for articles reporting an association between Dupuytren disease and diabetes 
mellitus, liver disease, and epilepsy published before September 26, 2016. The 
frequencies of Dupuytren disease and diabetes mellitus, liver disease, and epi-
lepsy were extracted, as was information on potential confounders. Generalized 
linear mixed models were applied to estimate pooled odds ratios, adjusted for 
confounders. Heterogeneity between studies was quantified using an intraclass 
correlation coefficient and was accounted for by a random effect for study. 
Results: One thousand two hundred sixty unique studies were identified, of 
which 32 were used in the meta-analyses. An association between Dupuytren 
disease and diabetes mellitus was observed (OR, 3.06; 95 percent CI, 2.69 to 
3.48, adjusted for age), which was stronger for type 1 diabetes mellitus than 
for type 2 diabetes mellitus but was not statistically significant (p = 0.24). An 
association between Dupuytren disease and liver disease was observed (OR, 
2.92; 95 percent CI, 2.08 to 4.12, adjusted for sex). Dupuytren disease and 
epilepsy were associated, yielding an OR of 2.80 (95 percent CI, 2.49 to 3.15). 
Heterogeneity between studies was moderate to low.
Conclusions: These findings demonstrate an association between Dupuytren 
disease and diabetes mellitus, liver disease, and epilepsy. Prospective, longi-
tudinal studies are needed to elucidate the pathways causing these associa-
tions. (Plast. Reconstr. Surg. 141: 367e, 2018.)
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disease has often been linked to diseases such as 
diabetes mellitus, liver disease, and epilepsy.4,8–12
In particular, diabetes mellitus has frequently 
been studied in relation to Dupuytren disease, 
and diabetes mellitus is considered an important 
risk factor for the development of Dupuytren dis-
ease.9,13,14 However, the studies reporting an asso-
ciation between Dupuytren disease and diabetes 
mellitus have conflicting results. In some stud-
ies, a strong association between the two condi-
tions was observed,15–17 but these results could not 
always be replicated in other studies.18,19
Liver disease has also frequently been asso-
ciated with Dupuytren disease, although it is 
thought that excessive alcohol consumption 
might be responsible for this association. There-
fore, it might be worthwhile to elucidate the role 
of alcohol consumption in this relation. The asso-
ciation between Dupuytren disease and epilepsy 
has frequently been the subject of study in older 
articles.20–24 Again, some studies reported this asso-
ciation and others did not. This discrepancy may 
be caused by the fact that Dupuytren disease is 
thought to be associated with specific anticonvul-
sant drugs, mainly barbiturates, that are not often 
prescribed anymore. This might explain why some 
recent studies did not demonstrate an association 
between Dupuytren disease and epilepsy.6,8
In summary, the precise relationship between 
Dupuytren disease and diabetes mellitus, liver 
disease, and epilepsy remains unclear. The dis-
crepancy in study results may be caused by hetero-
geneity between study populations. Also, the lack 
of controlling for age or sex as confounding factors 
might lead to an incorrect estimation of the associ-
ation. In addition, some small studies may individu-
ally be underpowered to show an association. Until 
now, no systematic review or meta-analysis has been 
conducted to estimate the strength of the associa-
tion between Dupuytren disease and diabetes mel-
litus, liver disease, and epilepsy. Therefore, the aim 
of the current study was to examine the strength 
and consistency of these associations in published 
studies reporting an association between Dupuy-
tren disease and diabetes mellitus, liver disease, 
and epilepsy, to end the ongoing debate about the 
role of diabetes mellitus, liver disease, and epilepsy 
as potential risk factors for Dupuytren disease.
PATIENTS AND METHODS
Literature Search and Article Assessment
A literature search was conducted on July 11, 
2013, using the MEDLINE, EMBASE, and Web of 
Science databases, using the queries reported in 
Table 1. These queries were formulated in cooper-
ation with an information specialist of our medical 
library. No restrictions on language or publication 
date were imposed. On September 16, 2016, the 
searches were updated.
Subsequently, two independent observers 
assessed the articles in three rounds, following 
the predefined inclusion and exclusion criteria as 
presented in Table 2. Although each article was 
assessed by only two observers, there were three 
observers in total [D.C.B., A.A.J.B. (see Acknowl-
edgement), and S.M.]. Observer D.C.B. assessed 
all articles. Because of circumstances, the activities 
of observer A.A.J.B. were discontinued and carried 
on by observer S.M. In the first round, the titles 
and abstracts were assessed. If no abstract was avail-
able, the keywords and Medical Subject Headings 
terms were assessed. In case the keywords or Medi-
cal Subject Headings terms contained Dupuytren 
disease (or Dupuytren contracture, or fibromato-
sis) in combination with diabetes mellitus, liver 
disease, or epilepsy, the full text was screened. In 
all rounds, inconsistencies were discussed to come 
to consensus. If consensus could not be reached, 
a third observer (P.M.N.W.) was consulted. Arti-
cles were included if they provided sufficient data 
to calculate either the prevalence of Dupuytren 
disease in diabetes mellitus, liver disease, or epi-
lepsy, or allowed the calculation of an odds ratio 
of these associations.
To correct for the confounding effect of age 
on the association between Dupuytren disease 
and diabetes mellitus, articles were included only 
if the age for both case and control groups was 
reported, or if the participants were matched on 
age. Sex is likely to be a confounder for the asso-
ciation between Dupuytren disease and liver dis-
ease; thus, we excluded the articles that did not 
report the sex in both case and control groups, 
or that did not match on sex. Because we could 
not identify potential confounders for the asso-
ciation between Dupuytren disease and epilepsy, 
there were no further exclusion criteria for this 
research question.
Data Extraction and Statistical Analyses
The primary outcome was the frequency 
of Dupuytren disease in the diabetes mellitus, 
liver disease, epilepsy, and control groups. The 
data were entered in a database by two observ-
ers independently. Articles that were published 
by the same authors having comparable titles 
were checked for data overlap. If the data over-
lap was larger than 50 percent, only the study 
reporting the most complete data was included 
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in the analyses. During the data extraction, the 
prevalence of Dupuytren disease was expressed 
in percentages of participants, and articles were 
excluded in case the prevalence was reported as 
percentages of hands.
Data were described by presenting the preva-
lence of Dupuytren disease, and ranges and for-
est plots are provided to show the odds ratios 
among studies. A generalized linear mixed model 
was used to estimate a pooled odds ratio using 
the procedure NLMIXED of SAS version 9.4 
(SAS Institute, Inc., Cary, N.C.). (See Document, 
Supple mental Digital Content 1, in which detailed 
information on the statistical analyses is reported, 
http://links.lww.com/PRS/C637.) The statistical 
analysis method used a generalized mixed model 
on the frequencies, with adjustment for potential 
confounders. Missing data on confounders were 
imputed.
Heterogeneity was calculated with the intra-
class correlation coefficient. The larger the 
intraclass correlation coefficient value, the larger 
the heterogeneity. This value can be interpreted 
as a measure of consistency. (See Document, 
 Supplemental Digital Content 1, in which detailed 
information on the statistical analyses is reported, 
http://links.lww.com/PRS/C637.) In all statistical 
analyses, a significance level of 5 percent was used.
RESULTS
Results of the Literature Search
The initial search yielded 1309 articles, of 
which 1260 were unique (Fig. 1). After assessing 
the titles and abstracts, 166 articles were subjected 
to full-text analysis. Some articles reported data 
on two of the three diseases. These articles were 
included in all full-text analyses for the two dis-
eases separately. This is the reason why the total 
number of articles included in the full-text analy-
sis for diabetes mellitus, epilepsy, and liver disease 
combined, as presented in Figure 1, is larger than 
166. In the full-text assessment round, the major-
ity of articles were excluded because there was no 
control group included in the study. In three arti-
cles, a questionnaire was used to diagnose Dupuy-
tren disease instead of a physical examination7,25,26; 
and in one article, the results were presented only 
for the number of hands, making it impossible 
to calculate an odds ratio on a participant level.27 
These articles were excluded from the analyses.
Of the 1260 unique articles that were 
obtained, 39 articles reported data on an asso-
ciation between Dupuytren disease and diabetes 
mellitus. Although many studies took the possible 
confounding effect of age into account by match-
ing, in some studies this was lacking.13,17,28–34 In a 
large number of articles, age was not reported 
for subgroups, nor were the participants matched 
on age.4,12,15,18,19,35–42 These articles were therefore 
excluded, along with five articles that reported 
incomplete data.27,43–46 A total of 21 articles were 
included in the meta-analysis on the association 
between Dupuytren disease and diabetes mellitus 
Table 1. Search Strategies Used for the Different Databases
Database Search Query
MEDLINE (“Dupuytren Contracture”[Mesh] OR dupuytren*[TIAB]) AND (Epidemiol*[TIAB] OR “ epidemiology” 
[Subheading] OR “etiology” [Subheading] OR associat*[TI] OR”Causality”[Mesh] OR “Epidemiologic 
Measurements”[Mesh])
EMBASE dupuytren*:ab,ti AND (‘epidemiology’:ab,ti OR ‘epidemiology’/exp OR ‘epidemiological data’/exp OR 
‘etiology’/de OR ‘disease association’/exp OR associat*:ti OR ‘risk factor’/exp OR ‘risk factor’:ab,ti) 
NOT [medline]/lim AND [embase]/lim
Web of Science TS=((dupuytren* AND (etiol* OR epidemiol*))) AND TI=((Dupuytren* OR fibromatos*)) AND 
TI=((etiol* OR epidemiol* OR associat*))
Table 2. Predefined Inclusion and Exclusion Criteria 
Used in the Different Rounds
Title and abstract
  Inclusion criterion
   Dupuytren disease as subject of research
  Exclusion criteria
   No original data/review
   Not about association of DD and DM, liver disease, or 
epilepsy
Full-text analysis
  Inclusion criterion
   Articles in Dutch, German, French, or English language
  Exclusion criteria
   Not about association of DD and DM, liver disease, or 
epilepsy
   No control group
   No physical examination performed to diagnose DD
   Case reports
   Conference abstract
   No original data
   Data overlap (>50%)
Data extraction
  Exclusion criteria
   No data reported on age or sex, nor matched for age 
or sex
   Incomplete data reported
DD, Dupuytren disease; DM, diabetes mellitus.
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Fig. 1. Flowchart of the study selection process. DD, Dupuytren disease.
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(Table 3). They all reported age of the diabetics 
and control group separately.
With respect to the association between 
Dupuytren disease and liver disease, nine articles 
reported data on an association (Table 4). In this 
association, a potential confounder is sex. The sex 
distribution was reported in almost all articles.36,47 
Two additional articles were excluded because 
they reported incomplete data.39,40 Thus, five arti-
cles entered the meta-analysis (Table 4). One of 
the included articles reported that participants 
were matched on age and sex, but the sex distri-
bution was not reported. The missing data on sex 
was imputed for this article.
Seven articles reported data on an associa-
tion between Dupuytren disease and epilepsy. 
However, six articles were included in the meta-
analysis (Table 5), because one article reported 
incomplete data.39 One of the included articles 
provided data that were separated for the differ-
ent types of anticonvulsant medication that the 
participants used.8
Dupuytren Disease and Diabetes Mellitus
The average prevalence of Dupuytren dis-
ease was 31 percent (range, 0.45 to 69 percent) 
in patients with diabetes mellitus (Table 3).48,49 In 
controls, the mean average prevalence was 14 per-
cent (range, 0.0 to 49 percent).16,49 An association 
between Dupuytren disease and diabetes mellitus 
(irrespective of the type) was found, indicated by 
a pooled odds ratio of 3.06 (95 percent CI, 2.69 
to 3.48). The heterogeneity between studies was 
moderate, indicated by an intraclass correlation 
coefficient of 0.56. This indicates that the con-
sistency was also moderate, which corresponds 
with the findings with respect to the odds ratios 
(Fig. 2).
Almost half of the studies specified the 
type of diabetes mellitus, or reported data 
for the different types of diabetes mellitus 
separately.13,16,28–30,50–53 For type 1 diabetes mellitus, 
the age-adjusted odds ratio was 3.90 (95 percent 
CI, 2.48 to 6.12), whereas for type 2 diabetes mel-
litus an odds ratio of 3.04 (95 percent CI, 2.18 to 
4.23) was found. A difference between the odds 
ratios of type 1 and type 2 diabetes mellitus could 
not be demonstrated (p = 0.24). Heterogeneity 
was low, as indicated by an intraclass correlation 
coefficient of 0.05.
Dupuytren Disease and Liver Disease
The average prevalence of Dupuytren disease 
was 22.3 percent (range, 18.9 to 47.4 percent) in 
patients with liver disease (Table 4).4,58 In controls, 
the average prevalence was 9.7 percent (range, 7.5 
to 14.0 percent).58,59 The sex-adjusted odds ratio 
of the association between Dupuytren disease 
and liver disease was 2.92 (95 percent CI, 2.08 to 
4.12). Heterogeneity was low, as indicated by an 
intraclass correlation coefficient of 0.05, indicat-
ing that the association between Dupuytren dis-
ease and liver disease was consistent (Fig. 3). The 
majority of the studies included participants with 
liver cirrhosis,4,57–59 and two articles made a distinc-
tion between alcoholic and nonalcoholic liver cir-
rhosis.4,59 In one article, the type of liver disease 
was not reported.60
Dupuytren Disease and Epilepsy
The average prevalence of Dupuytren disease 
was 40.3 percent (range, 7.9 to 70.5 percent) in 
patients with epilepsy (Table 5).49,61 In controls, 
the average prevalence was 29.2 percent (range, 
6.0 to 49.2 percent).49,61 There was an association 
between Dupuytren disease and epilepsy (OR, 
2.80; 95 percent CI, 2.49 to 3.15). One of these 
studies provided an odds ratio that was smaller 
than 1, indicating that epileptic patients were 
less likely to have Dupuytren disease in this study 
(Fig. 4). The heterogeneity between studies was 
moderate, as indicated by an intraclass correla-
tion coefficient of 0.55. Unfortunately, only one 
study reported frequencies for different medica-
tion types,8 and thus further analyses on medica-
tion were not possible.
DISCUSSION
This meta-analysis showed that Dupuytren dis-
ease and diabetes mellitus are strongly associated, 
even after adjustment for age differences between 
groups. Furthermore, an association between 
Dupuytren disease and liver disease adjusted for 
sex, and between Dupuytren disease and epilepsy 
was found.
The finding that Dupuytren disease and 
diabetes mellitus are associated suggests that 
Dupuytren disease and diabetes mellitus may 
have common factors that contribute to their 
pathogenesis. The suspected disease mechanism 
relates to biochemical changes that occur as a 
result of diabetes mellitus. It is known that many 
complications of diabetes mellitus are caused by 
nonenzymatic glycation of proteins. In the lit-
erature, there is increasing evidence for the role 
of nonenzymatic glycation in fibrotic diseases 
that are associated with diabetes mellitus, such 
as cardiomyopathy.62,63 The biochemical changes 
372e
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that occur as a result of diabetes mellitus cause 
oxidative stress that produces advanced-glycated 
end-products.63,64 Advanced-glycated end-prod-
ucts interact with advanced-glycated end-product 
receptors present on cell surfaces, which causes 
up-regulation of transforming growth factor 
(TGF)-β.65 TGF-β plays a key role in the pathol-
ogy of fibrotic diseases, and up-regulation has 
been associated with Dupuytren disease.66,67 In 
addition, the up-regulation of TGF-β also causes 
synthesis of type III collagen, the type of collagen 
that is predominantly found in Dupuytren disease 
tissue.68,69 Moreover, collagen tends to stiffen by 
cross-linking because of nonenzymatic glycation.70 
Furthermore, biochemical studies have shown 
that diabetes mellitus metabolites stimulate the 
development of myofibroblasts,71 the most impor-
tant cell in Dupuytren disease nodules. Thus, it 
has been shown that biochemical consequences 
of diabetes mellitus play an important role in 
fibrotic diseases. Therefore, it is likely that the 
same pathogenic pathways underlie the associa-
tion between Dupuytren disease and diabetes mel-
litus. In addition, it is possible that the peripheral 
vascular changes that can occur as a consequence 
of diabetes mellitus aggravate the oxidative stress. 
This has previously been suggested as a trigger for 
Dupuytren disease.72,73 There was no statistically 
significant difference between the odds ratio of 
diabetes mellitus type 1 and type 2.
We further demonstrated an association 
between Dupuytren disease and liver disease, 
although the type of liver disease could not be 
addressed in the meta-analysis, because the data 
were not reported separately. Unfortunately, the 
effect of alcohol consumption in this association 
could not be determined either, because only one 
included article reported the amount of alcohol 
consumed in each group.4 However, we were able 
to correct the analysis for differences in sex dis-
tribution. Multiple studies have shown that men 
consume more alcohol than women,74–77 although 
this difference has become less pronounced in 
the past decade.78 Therefore, sex can be consid-
ered as a proxy variable for alcohol consumption. 
This way, one could argue that our analyses were 
corrected for the indirect effects of alcohol con-
sumption. Interestingly, animal studies indicate 
that the formation of advanced-glycated end-prod-
ucts also plays a role in alcoholic liver disease.79 
Furthermore, both diabetes mellitus and alcohol 
consumption are responsible for alterations in 
glucose homeostasis.80,81
Our results showed that Dupuytren disease 
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role of anticonvulsant medication could not be 
defined in this meta-analysis. However, one article 
that studied the association between Dupuytren 
disease and epilepsy reported data for each medi-
cation type separately.8 In this article, an associa-
tion between the two diseases was demonstrated, 
but no associations between specific anticonvul-
sants and Dupuytren disease were found. The 
authors argue that the association between the 
two diseases might be caused by ascertainment 
bias.
Publication bias is always a concern in meta-
analyses. However, we did not look for funnel plot 
asymmetry, as the number of included articles was 
small. This was especially the case in the meta-
analysis of Dupuytren disease and liver disease, 
Fig. 2. Forest plot showing the association between Dupuytren disease and 
diabetes mellitus as calculated from the different articles. The size of the 
square indicates the weight of the study. The horizontal lines represent the 
95 percent confidence interval. Note that this figure shows crude odds ratios.
Fig. 3. Forest plot showing the association between Dupuytren disease and 
liver disease as calculated from the different articles. The size of the square 
indicates the weight of the study. Note that this figure shows crude odds 
ratios.
376e
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and epilepsy. The statistical tests would lack power 
to identify asymmetry. Moreover, commonly used 
tests such as the Begg test or the Egger test can-
not be used, because the outcome in this study is 
dichotomous. There are alternatives for examin-
ing funnel plot asymmetry in these cases82 that are 
available in software packages such as R. However, 
these methods cannot manage meta-analyses in 
which covariates are included.
Although we planned to correct the associa-
tion between Dupuytren disease and liver disease 
for the amount of alcohol consumed, this was not 
possible, because those data were not reported in 
the included studies. In such cases, it is advised to 
contact the authors for additional information. 
However, the included articles were published 
more than 20 years ago (1956 to 1992), making it 
difficult to contact the authors. Therefore, we want 
to emphasize that the results of our meta-analyses 
do not present information about causality. Fur-
thermore, there were two articles in the association 
between Dupuytren disease and liver disease with a 
confidence interval overlapping 1.0. This indicates 
that the association was not significant, whereas 
the other articles demonstrated a significant asso-
ciation. However, the intraclass correlation coef-
ficient indicated that heterogeneity was very low. 
Although this may seem contradictory, the point 
estimates of these studies were above an odds ratio 
of 1.0. The low intraclass correlation coefficient 
value ensures that this overlap is not caused by 
heterogeneity, but rather by a lack of sample size 
within studies, leading to a wide confidence inter-
val. The same was seen in the association between 
Dupuytren disease and diabetes mellitus.
A weakness of this study is that the quality of 
the articles was not determined using a quality 
assessment tool. We had several reasons for this. 
First, there is no single quality assessment tool 
available for observational studies.83,84 Second, 
and more importantly, there are multiple studies 
indicating that a quality score should not be used 
to weight, rank, or value the articles included in a 
meta-analysis.85–88 Furthermore, the quality assess-
ment score is often not related to effect size and 
heterogeneity.89 The Cochrane Collaboration pro-
vides an alternative judgment system, evaluating 
risk of bias. However, this system is focused on 
randomized controlled trials and not on observa-
tional studies.
We noticed that the definition of Dupuytren 
disease varied widely across studies. For exam-
ple, some authors did not report anything about 
the definition at all,8,32,59 whereas others clearly 
stated the definition they used for Dupuytren 
disease.23,28,58 (See Table, Supplemental Digital 
Content 2, in which details on diagnosis and defi-
nitions of Dupuytren disease and diabetes melli-
tus are reported, along with definitions of control 
groups and information on age as a potential 
confounder, http://links.lww.com/PRS/C638. See 
Table, Supplemental Digital Content 3, in which 
details on diagnosis and definitions of Dupuytren 
disease are reported, along with definitions of con-
trol groups and information on sex as a potential 
confounder, http://links.lww.com/PRS/C639. See 
Table, Supplemental Digital Content 4, in which 
details on diagnosis and definitions of Dupuytren 
disease are reported, along with definitions of con-
trol groups, http://links.lww.com/PRS/C640.) Some 
only took alterations in the fourth or fifth digit 
into account.33,54 Furthermore, the populations 
from which the control subjects were selected 
were diverse. In some studies, the controls were 
randomly selected from the general population,32 
whereas in other studies the controls were patients 
from a specific hospital department.28 Although 
this increases the variability between studies, it 
would lead to an underestimation of the associa-
tion strength rather than an overestimation.
Fig. 4. Forest plot showing the association between Dupuytren disease and 
epilepsy as calculated from the different articles. The size of the square indi-
cates the weight of the study.
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Because of the correction for potential con-
founders, the results of these meta-analyses pro-
vide a more reliable estimation of the association 
between Dupuytren disease and diabetes mellitus, 
liver disease, and epilepsy. Future studies should 
elucidate the causal pathways that underlie these 
associations. Until then, clinicians and research-
ers studying Dupuytren disease should be aware 
of these associations and correct for them in their 
study design or analyses.
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